Ingalls & Snyder LLC’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.34M | Sell |
3,012
-215
| -7% | -$100K | 0.05% | 193 |
|
|
2025
Q4 | $1.46M | Buy |
3,227
+12
| +0.4% | +$5.17K | 0.05% | 189 |
|
|
2025
Q3 | $1.26M | Sell |
3,215
-69
| -2% | -$28.8K | 0.04% | 208 |
|
|
2025
Q2 | $1.46M | Sell |
3,284
-40
| -1% | -$18.4K | 0.05% | 190 |
|
|
2025
Q1 | $1.61M | Buy |
3,324
+334
| +11% | +$156K | 0.05% | 169 |
|
|
2024
Q4 | $1.2M | Buy |
2,990
+2,000
| +202% | +$927K | 0.05% | 202 |
|
|
2024
Q3 | $460K | Buy |
990
+63
| +7% | +$30.3K | 0.02% | 312 |
|
|
2024
Q2 | $435K | Sell |
927
-106
| -10% | -$46K | 0.02% | 301 |
|
|
2024
Q1 | $432K | Hold |
1,033
| – | – | 0.02% | 310 |
|
|
2023
Q4 | $420K | Buy |
1,033
+29
| +3% | +$10.7K | 0.02% | 303 |
|
|
2023
Q3 | $349K | Hold |
1,004
| – | – | 0.02% | 321 |
|
|
2023
Q2 | $353K | Hold |
1,004
| – | – | 0.02% | 327 |
|
|
2023
Q1 | $316K | Hold |
1,004
| – | – | 0.02% | 334 |
|
|
2022
Q4 | $290K | Hold |
1,004
| – | – | 0.02% | 349 |
|
|
2022
Q3 | $291K | Hold |
1,004
| – | – | 0.02% | 340 |
|
|
2022
Q2 | $283K | Sell |
1,004
-7
| -0.7% | -$1.87K | 0.01% | 355 |
|
|
2022
Q1 | $264K | Buy |
1,011
+4
| +0.4% | +$949 | 0.01% | 397 |
|
|
2021
Q4 | $221K | Buy |
+1,007
| New | +$196K | 0.01% | 432 |
|
|
2021
Q3 | – | Sell |
-1,007
| Closed | -$203K | – | 473 |
|
|
2021
Q2 | $203K | Sell |
1,007
-193
| -16% | -$40.4K | 0.01% | 439 |
|
|
2021
Q1 | $258K | Hold |
1,200
| – | – | 0.01% | 382 |
|
|
2020
Q4 | $284K | Hold |
1,200
| – | – | 0.01% | 353 |
|
|
2020
Q3 | $327K | Hold |
1,200
| – | – | 0.02% | 284 |
|
|
2020
Q2 | $348K | Sell |
1,200
-2,450
| -67% | -$664K | 0.02% | 303 |
|
|
2020
Q1 | $869K | Buy |
3,650
+2,450
| +204% | +$562K | 0.06% | 211 |
|
|
2019
Q4 | $263K | Hold |
1,200
| – | – | 0.01% | 341 |
|
|
2019
Q3 | $203K | Hold |
1,200
| – | – | 0.01% | 398 |
|
|
2019
Q2 | $220K | Hold |
1,200
| – | – | 0.01% | 390 |
|
|
2019
Q1 | $221K | Buy |
+1,200
| New | +$222K | 0.01% | 384 |
|
|
2018
Q4 | – | Sell |
-1,200
| Closed | -$231K | – | 447 |
|
|
2018
Q3 | $231K | Hold |
1,200
| – | – | 0.01% | 397 |
|
|
2018
Q2 | $204K | Buy |
+1,200
| New | +$186K | 0.01% | 376 |
|
|
2017
Q4 | – | Sell |
-3,270
| Closed | -$497K | – | 420 |
|
|
2017
Q3 | $497K | Hold |
3,270
| – | – | 0.03% | 246 |
|
|
2017
Q2 | $421K | Buy |
3,270
+800
| +32% | +$96.3K | 0.02% | 251 |
|
|
2017
Q1 | $270K | Buy |
+2,470
| New | +$217K | 0.01% | 325 |
|
Other funds holding VRTX
VCM
VPM
Ingalls & Snyder LLC's VRTX Position: Q1 2026 in Review
Ingalls & Snyder LLC reduced its Vertex Pharmaceuticals (VRTX) stake by 6.7% in Q1 2026, selling an estimated $100K and leaving 3,012 shares worth $1.34M. The position accounts for 0.05% of the portfolio, ranked #193.
Ingalls & Snyder LLC first reported a position in VRTX in Q1 2017 and has held it in 33 quarters since. The position peaked at $1.61M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Ingalls & Snyder LLC held 3,012 shares of Vertex Pharmaceuticals worth $1.34M as of Q1 2026.
- Ingalls & Snyder LLC sold 215 Vertex Pharmaceuticals shares in Q1 2026, an estimated $100K.
- Vertex Pharmaceuticals made up 0.05% of Ingalls & Snyder LLC's portfolio in Q1 2026, its #193 holding.
- Ingalls & Snyder LLC first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 33 quarters since.
- Ingalls & Snyder LLC's Vertex Pharmaceuticals position peaked at $1.61M in Q1 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Ingalls & Snyder LLC's 13F filing for Q1 2026, filed 13 May 2026.